NEW YORK

,

Oct. 2, 2020

/PRNewswire/ — Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) between

February 28, 2020

and

August 18, 2020

, inclusive (the “Class Period”). The lawsuit seeks to recover damages for BioMarin investors under the federal securities laws.

To join the BioMarin class action, go to

http://www.rosenlegal.com/cases-register-1960.html

or call

Phillip Kim, Esq.

toll-free at 866-767-3653 or email

[email protected]

or

[email protected]

for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec’s durability of effect; (2) as a result, it was foreseeable that the U.S. Food and Drug Administration (“FDA”) would not approve the Biologics License Application (“BLA”) for valoctocogene roxaparvovec without additional data; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court

no later than

November 24, 2020


. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to

http://www.rosenlegal.com/cases-register-1960.html

or to discuss your rights or interests regarding this class action, please contact

Phillip Kim, Esq.

of Rosen Law Firm toll free at 866-767-3653 or via e-mail at

[email protected]

or

[email protected]

.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn:

https://www.linkedin.com/company/the-rosen-law-firm

, on Twitter:

Tweets by rosen_firm

or on Facebook:

https://www.facebook.com/rosenlawfirm/

.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.



Phillip Kim, Esq.


The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor


New York, NY

10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827


[email protected]



[email protected]



[email protected]



www.rosenlegal.com

View original content to download multimedia:

http://www.prnewswire.com/news-releases/rosen-a-leading-investor-rights-law-firm-announces-filing-of-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-encourages-investors-with-losses-in-excess-of-100k-to-contact-firm–bmrn-301145118.html

SOURCE Rosen Law Firm, P.A.